Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25599265 | 0.92 | ACACB (0.34) | ACACBITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25599395 | 0.85 | ACACB (0.32) | ACACBITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25599311 | 0.83 | ITGB3 (0.32) | ACACBITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25599307 | 0.83 | ITGB1 (0.34) | SCN9AITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25599487 | 0.82 | GPR132 (0.34) | ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25599298 | 0.82 | CXCR2 (0.35) | ITGB1 | |
| SCHEMBL25599317 | 0.81 | CXCR2 (0.37) | ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL23460916 | 0.81 | CNR2 (0.40) | ACACBSCN9ASCN5AITGB3ITGB1 | |
| SCHEMBL23460918 | 0.81 | CNR2 (0.40) | ACACBSCN9ASCN5AITGB3ITGB1 | |
| SCHEMBL23460891 | 0.78 | ACACB (0.37) | ACACBSCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | ACACB 1130/4885SCN9A 643/4885SCN5A 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.